Large language models to identify social determinants of health in electronic health records
Marco Guevara-Vega(Brigham and Women's Hospital), Danielle S. Bitterman(Brigham and Women's Hospital), Jack M. Qian(Brigham and Women's Hospital), Spencer A. Thomas(Brigham and Women's Hospital), Idalid Franco(Brigham and Women's Hospital), Tafadzwa L. Chaunzwa(Dana-Farber Cancer Institute), Raymond H. Mak(Brigham and Women's Hospital), Paul J. Catalano(Computational Physics (United States)), Shalini Moningi(Brigham and Women's Hospital), Shan Chen(Brigham and Women's Hospital), Guergana Savova(Boston Children's Hospital), Madeleine Goldstein(Dana-Farber Cancer Institute), Hugo J.W.L. Aerts(Maastro Clinic), Susan Harper(Dana-Farber Cancer Institute), Benjamin H. Kann(Brigham and Women's Hospital)
Cited by 249
Related Papers
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Patients' Expectations about Effects of Chemotherapy for Advanced Cancer
|New England Journal of Medicine|2012|1.1k
Artificial intelligence in radiation oncology
|Nature Reviews Clinical Oncology|2020|399
High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200
|Journal of Clinical Oncology|2005|344
The TRIPOD-LLM reporting guideline for studies using large language models
|Nature Medicine|2025|340